FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1987649909> ?p ?o ?g. }

• W1987649909 abstract "Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, ILCD326 is one of the first and prominent immunotherapeutic targets in cancer therapy due to its frequent and high-level expression on most carcinomas of various origins. The dominant role of cytotoxic T cells for tumor suppression and surveillance in vivo is well documented in literature. A novel bi-specific antibody AbGn-100 was constructed, in which the antigen-binding domain of an anti- human CD326 antibody was linked to the antigen-binding domain of an anti-human T cell receptor (TCR) ≤ chain antibody. Human serum albumin was incorporated into this construct to prolong the half life in vivo. This bi-specific antibody is able to direct T cells toward CD326-expressing cancer cells to execute T cell cytotoxic function after TCR cross-linking mediated by CD326 expressed on cancer cells while it remains harmless when either T cells or CD326-expressing cancer cells is absent. In vitro cytotoxicity assays with PBMCs from different donors have demonstrated potent (up to 60% above the background) cytotoxicity eliciting activity of AbGn-100 to lung (NCI-H358), ovarian (OMC3) and colorectal (COLO205) cancer cells lines. In the absence of cancer cells, the addition of AbGn-100 didn't trigger the up-regulation of T cell activation markers such as CD25 or CD69, nor did it increase the secretion of cytokines such as IL-2 and Interferon β, demonstrating the safety profile of AbGn-100. In vivo activity of AbGn-100 was tested with established lung (NCI-H358) and ovarian (OMC-3) cancer xenografts in NOD-SCID mice. AbGn-100, in the presence of human PBMC, significantly reduced the size of the established lung and ovarian tumors. Most notably, in some of the mice, tumor was not detectable after 50 days of treatment, suggesting the possibility of tumor eradication. PK studies in mice showed the half-life of AbGn-100 to be around 20 hours, which is substantially longer than conventional single-chain Fv bi-specific antibodies. These data support the potential of further development of AbGn-100 as therapeutics for the treatment of CD326-expressing solid tumors.Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3527. doi:1538-7445.AM2012-3527" @default.
• W1987649909 created "2016-06-24" @default.
• W1987649909 creator A5026072615 @default.
• W1987649909 creator A5038587440 @default.
• W1987649909 creator A5051792135 @default.
• W1987649909 creator A5053232339 @default.
• W1987649909 creator A5058132826 @default.
• W1987649909 creator A5063623707 @default.
• W1987649909 creator A5077266484 @default.
• W1987649909 date "2012-04-15" @default.
• W1987649909 modified "2023-09-25" @default.
• W1987649909 title "Abstract 3527: Potent anti-tumor activity of AbGn-100, an anti-CD326 x anti-TCR bispecific antibody to CD326-expressing solid tumors" @default.
• W1987649909 doi "https://doi.org/10.1158/1538-7445.am2012-3527" @default.
• W1987649909 hasPublicationYear "2012" @default.
• W1987649909 type Work @default.
• W1987649909 sameAs 1987649909 @default.
• W1987649909 citedByCount "0" @default.
• W1987649909 crossrefType "proceedings-article" @default.
• W1987649909 hasAuthorship W1987649909A5026072615 @default.
• W1987649909 hasAuthorship W1987649909A5038587440 @default.
• W1987649909 hasAuthorship W1987649909A5051792135 @default.
• W1987649909 hasAuthorship W1987649909A5053232339 @default.
• W1987649909 hasAuthorship W1987649909A5058132826 @default.
• W1987649909 hasAuthorship W1987649909A5063623707 @default.
• W1987649909 hasAuthorship W1987649909A5077266484 @default.
• W1987649909 hasConcept C109316439 @default.
• W1987649909 hasConcept C121608353 @default.
• W1987649909 hasConcept C126322002 @default.
• W1987649909 hasConcept C147483822 @default.
• W1987649909 hasConcept C150903083 @default.
• W1987649909 hasConcept C154317977 @default.
• W1987649909 hasConcept C159654299 @default.
• W1987649909 hasConcept C202751555 @default.
• W1987649909 hasConcept C203014093 @default.
• W1987649909 hasConcept C207001950 @default.
• W1987649909 hasConcept C2777701055 @default.
• W1987649909 hasConcept C502942594 @default.
• W1987649909 hasConcept C55493867 @default.
• W1987649909 hasConcept C71924100 @default.
• W1987649909 hasConcept C86803240 @default.
• W1987649909 hasConceptScore W1987649909C109316439 @default.
• W1987649909 hasConceptScore W1987649909C121608353 @default.
• W1987649909 hasConceptScore W1987649909C126322002 @default.
• W1987649909 hasConceptScore W1987649909C147483822 @default.
• W1987649909 hasConceptScore W1987649909C150903083 @default.
• W1987649909 hasConceptScore W1987649909C154317977 @default.
• W1987649909 hasConceptScore W1987649909C159654299 @default.
• W1987649909 hasConceptScore W1987649909C202751555 @default.
• W1987649909 hasConceptScore W1987649909C203014093 @default.
• W1987649909 hasConceptScore W1987649909C207001950 @default.
• W1987649909 hasConceptScore W1987649909C2777701055 @default.
• W1987649909 hasConceptScore W1987649909C502942594 @default.
• W1987649909 hasConceptScore W1987649909C55493867 @default.
• W1987649909 hasConceptScore W1987649909C71924100 @default.
• W1987649909 hasConceptScore W1987649909C86803240 @default.
• W1987649909 hasLocation W19876499091 @default.
• W1987649909 hasOpenAccess W1987649909 @default.
• W1987649909 hasPrimaryLocation W19876499091 @default.
• W1987649909 hasRelatedWork W2004879789 @default.
• W1987649909 hasRelatedWork W2030204783 @default.
• W1987649909 hasRelatedWork W2049133947 @default.
• W1987649909 hasRelatedWork W2057114572 @default.
• W1987649909 hasRelatedWork W2058114535 @default.
• W1987649909 hasRelatedWork W2076844516 @default.
• W1987649909 hasRelatedWork W2085811812 @default.
• W1987649909 hasRelatedWork W2107335150 @default.
• W1987649909 hasRelatedWork W2147828284 @default.
• W1987649909 hasRelatedWork W2337778663 @default.
• W1987649909 hasRelatedWork W2497474405 @default.
• W1987649909 hasRelatedWork W2524819444 @default.
• W1987649909 hasRelatedWork W2550234446 @default.
• W1987649909 hasRelatedWork W2573020009 @default.
• W1987649909 hasRelatedWork W2766016309 @default.
• W1987649909 hasRelatedWork W3081641895 @default.
• W1987649909 hasRelatedWork W3104783726 @default.
• W1987649909 hasRelatedWork W3180031061 @default.
• W1987649909 hasRelatedWork W3183033555 @default.
• W1987649909 hasRelatedWork W3206392010 @default.
• W1987649909 isParatext "false" @default.
• W1987649909 isRetracted "false" @default.
• W1987649909 magId "1987649909" @default.
• W1987649909 workType "article" @default.